Kala Pharmaceuticals (KALA) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KALA shares.
View KALA analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12-month target prices for Kala Pharmaceuticals' shares. Their KALA share price forecasts range from $24.00 to $47.00. On average, they expect the company's share price to reach $35.50 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price.
View analysts price targets for KALA or view top-rated stocks among Wall Street analysts.

Kala Pharmaceuticals' stock was trading at $38.15 at the beginning of the year. Since then, KALA stock has decreased by 60.9% and is now trading at $14.91.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our KALA earnings forecast.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) posted its earnings results on Tuesday, May, 9th. The company reported ($6.99) EPS for the quarter, missing the consensus estimate of ($5.10) by $1.89. Kala Pharmaceuticals had a negative net margin of 1,383.91% and a negative trailing twelve-month return on equity of 1,062.69%.

Kala Pharmaceuticals's stock reverse split on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

1 employees have rated Kala Pharmaceuticals Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%), BlackRock Inc. (1.05%), Jane Street Group LLC (0.53%), Bank of America Corp DE (0.26%), UBS Group AG (0.09%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Eric Trachtenberg, Hongming Chen, Mark T Iwicki, Mark T Iwicki, Mary Reumuth, Ra Capital Management, LP, Romulus K Brazzell and Todd Bazemore.
View institutional ownership trends.

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KALA stock can currently be purchased for approximately $14.91.

Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $35.04 million and generates $3.89 million in revenue each year. The company earns $-44,820,000.00 in net income (profit) each year or ($14.71) on an earnings per share basis.

The company employs 192 workers across the globe.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for the company is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399.